Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin’s lymphoma (B-NHL) chemotherapy: a meta-analysis

References

• Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics. CA Cancer J Clin. 2008;58:71–96.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin’s lymphomas:clinical features of the major histologic subtypes. Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol. 1998;16:2780–95.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.
   PubMed Web of Science ®Google Scholar
• Forspointner R, Dreylin M, Repp R, Hermann S, Hänel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064–71.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–7.
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, Neser S, Al-Ali KH, Neubauer A, et al. Rituximab added to first-line mitoxantrone,chlorambucil, and prednisolone chemotherapy followed by Interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an east German study group hematology and oncology study. J Clin Oncol. 2007;25:1986–92.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725–32.
   PubMed Web of Science ®Google Scholar
• Ketterer N, Coiffier B, Thieblemont C, Fermé C, Brière J, Casasnovas O. Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B). Annals Oncol. 2013;24:1032–7.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Österborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomized controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379–91.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Céligny P, Warzocha K, Loscertales J, Catalano J, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756–65.
   PubMed Web of Science ®Google Scholar
• Grillo-López AJ, White CA, Dallaire BK, Varns CL, Shen CD, Wei A, et al. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol. 2000;1:1–9.
   PubMedGoogle Scholar
• Leget GA, Czuczman MS. Use of rituximab, the new FDA-approved antibody. Curr Opin Oncol. 1998;10:548–51.
   PubMedGoogle Scholar
• King KM, Younes A. Rituximab: review and clinical applications focusing on non-Hodgkin’slymphoma. Expert Rev Anticancer Ther. 2001;1:177–86.
   PubMedGoogle Scholar
• Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, et al. Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet. 2013;381:1817–26.
   PubMed Web of Science ®Google Scholar
• Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31:1662–8.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Plos Med. 2009;6:e1000097.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0, National Institutes of Health National Cancer Institute; 2009..
   Google Scholar
• Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.
   PubMedGoogle Scholar
• Tobinai K, Igarashi T, Itoh K, Kurosawa M, Nagai H, Hiraoka A, et al. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B-cell non-Hodgkin lymphomamostly pretreated with rituximab: a multicenter phase II study. Cancer Sci. 2011;102:1698–705.
   PubMed Web of Science ®Google Scholar
• Gao G, Liang X, Jiang J, Zhou X, Huang R, Chu Z, et al. A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin’s lymphoma. Acta Oncol. 2010;49:3–12.
   PubMed Web of Science ®Google Scholar
• Liu JP. Rethinking statistical approaches to evaluating drug safety. Yonsei Med J. 2007;48:895–900.
   PubMed Web of Science ®Google Scholar
• Gallagher EJ. No proof of a difference is not equivalent to proof of no difference. J Emerg Med. 1994;2:525–7.
   Google Scholar
• Askeland G. Rituximab chemotherapy regimens for treating advanced follicularlymphoma evaluated in new study. Expert Rev Clin Immunol. 2013;9:40224.
   Google Scholar
• Verschuuren EA, Stevens SJ, van Imhoff GW, Middeldorp JM, de Boer C, Koeter G, et al. Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication. Transplantation. 2002;73:100–4.
   PubMed Web of Science ®Google Scholar
• Saikia TK, Menon H, Advani SH. Prolonged neutropenia following anti CD20 therapy in a patient with relapsed follicular non-Hodgkin’s lymphoma and corrected with IVIG. Ann Oncol. 2001;12:1493–4.
   PubMed Web of Science ®Google Scholar
• Yokohama A, Tsukamoto N, Uchiumi H, Handa H, Matsushima T, Karasawa M, et al. Durable remission induced by rituximab-containing chemotherapy in a patient with primary refractory Burkitt’s lymphoma. Ann Hematol. 2004;83:120–3.
   PubMed Web of Science ®Google Scholar
• Lee MY, Chiou TJ, Hsiao LT, Yang MH, Lin PC, Poh SB. Rituximab therapy increased post-transplant cytomegalovirus complications in Non-Hodgkin’s lymphoma patients receiving autologous hematopoietic stem cell transplantation. Ann Hematol. 2008;87:285–9.
   PubMed Web of Science ®Google Scholar
• Lin PC, Hsiao LT, Poh SB, Wang WS, Yen CC, Chao TC, et al. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP. Ann Hematol. 2007;86:95–100.
   PubMed Web of Science ®Google Scholar
• Unluturk U, Aksoy S, Yonem O, Bayraktar Y, Tekuzman G. Cytomegalovirus gastritis after rituximab treatment in a non-Hodgkin’s lymphoma patient. World J Gastroenterol. 2006;12:1978–9.
   PubMed Web of Science ®Google Scholar
• Aksoy S, Harputluoglu H, Kilickap S, Dede DS, Dizdar O, Altundag K, et al. Rituximab-related viral infections in lymphoma patients. Leuk Lymphoma. 2007;48:1307–12.
   PubMed Web of Science ®Google Scholar
• Vidal L, Gafter-Gvili A, Leibovici L, Shpilberg O. Rituximab as maintenance therapy for patients with follicular lymphoma. Cochrane Database Syst Rev. 2009;2:CD006552.
   PubMedGoogle Scholar
• Lanini S, Molloy AC, Fine PE, Prentice AG, Ippolito G, Kibbler CC. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med. 2011;9:36.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Xiu Y, Komura K, Nimmerjahn F, Tedder TF. Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20immunotherapy. J Exp Med. 2006;203:743–53.
   PubMed Web of Science ®Google Scholar
• Hoyer BF, Manz RA, Radbruch A, Hiepe F. Long-lived plasma cells and their contribution to autoimmunity. Ann N Y Acad Sci. 2005;1050:124–33.
   PubMed Web of Science ®Google Scholar
• Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford). 2001;40:205–11.
   PubMed Web of Science ®Google Scholar
• Nishio M, Endo T, Fujimoto K, Sato N, Sakai T, Obara M, et al. Persistent panhypogammaglobulinemia with selected loss of memory B cells and impaired isotype expression after rituximab therapy for post-transplant EBV-associated autoimmune hemolytic anemia. Eur J Haematol. 2005;75:527–9.
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106:1538–43.
   PubMed Web of Science ®Google Scholar
• Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007;45:507–39.
   PubMed Web of Science ®Google Scholar